Search

AbbVie Inc

Open

BrancheGesundheitswesen

262.83 -1.11

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

260.05

Max

266.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9B

3.6B

Verkäufe

2B

17B

KGV

Branchendurchschnitt

74.723

57.366

EPS

3.65

Dividendenrendite

2.58

Gewinnspanne

21.283

Angestellte

57,000

EBITDA

5B

8.7B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+5.38% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

2.58%

2.16%

Nächstes Ergebnis

30. Okt. 2026

Nächste Dividendenausschüttung

13. Nov. 2026

Nächstes Ex-Dividendendatum

14. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

14B

467B

Vorheriger Eröffnungskurs

263.94

Vorheriger Schlusskurs

262.83

Nachrichtenstimmung

By Acuity

22%

78%

65 / 340 Ranking in Healthcare

AbbVie Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Aug. 2026, 20:07 UTC

AbbVie Inc shares are higher, supported by favorable macro conditions and lower Treasury yields. The stock is trading near the upper end of its one-month range.

24. Aug. 2026, 19:36 UTC

AbbVie Inc. shares are trading lower today, having reached a session low earlier. The stock remains above its 20-day moving average.

21. Aug. 2026, 20:06 UTC

News

AbbVie Inc is set to present new data on its bispecific antibody at the 2026 World Conference on Lung Cancer, boosting investor sentiment. Shares are higher today.

20. Aug. 2026, 19:31 UTC

News
Correlated Moves

AbbVie shares are lower today, despite Piper Sandler raising its price target to $303 from $298. The decline aligns with broader sector weakness.

19. Aug. 2026, 23:01 UTC

AbbVie Inc. is lower in after-market trading, driven by declines in the Biotechnology sub-sector. Recent sessions had shown upward momentum.

18. Aug. 2026, 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

17. Aug. 2026, 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

14. Aug. 2026, 19:46 UTC

Social Media

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.

13. Aug. 2026, 23:21 UTC

Abbvie Inc shares are lower in after-market hours, with no specific news identified for the decline. Initial jobless claims rose unexpectedly today.

12. Aug. 2026, 20:06 UTC

News
Macro Event

AbbVie Inc. shares are lower today, continuing a decline since Tuesday's close, despite FDA acceptance of a BOTOX Cosmetic application for jawline contouring.

11. Aug. 2026, 20:06 UTC

News

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

10. Aug. 2026, 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

7. Aug. 2026, 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6. Aug. 2026, 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5. Aug. 2026, 19:26 UTC

News
Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4. Aug. 2026, 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3. Aug. 2026, 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31. Juli 2026, 20:04 UTC

News
Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30. Juli 2026, 22:41 UTC

Social Media
Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29. Juli 2026, 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28. Juli 2026, 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27. Juli 2026, 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24. Juli 2026, 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23. Juli 2026, 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22. Juli 2026, 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21. Juli 2026, 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20. Juli 2026, 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Peer-Vergleich

Kursveränderung

AbbVie Inc Prognose

Kursziel

By TipRanks

5.38% Vorteil

12-Monats-Prognose

Durchschnitt 280.1 USD  5.38%

Hoch 303 USD

Tief 225 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AbbVie Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

23 ratings

19

Buy

4

Halten

0

Sell

Stimmung

By Acuity

65 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
help-icon Live chat